Compare · ELAB vs NVO
ELAB vs NVO
Side-by-side comparison of PMGC Holdings Inc. (ELAB) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELAB and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $227.95B, about 46025.5x ELAB ($5.0M).
- Over the past year, ELAB is down 99.4% and NVO is down 23.0% - NVO leads by 76.4 points.
- ELAB has been more active in the news (8 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for ELAB).
- Company
- PMGC Holdings Inc.
- Novo Nordisk A/S
- Price
- $1.06-3.64%
- $50.28-2.30%
- Market cap
- $5.0M
- $227.95B
- 1M return
- -26.64%
- +15.41%
- 1Y return
- -99.45%
- -23.02%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 8
- 5
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ELAB
- NorthStrive Defense Tech Executes Definitive Exclusive License Agreement with Florida State University Research Foundation for Multi-Domain Drone Payload Technology Across Defense, Aerospace and Maritime Applications
- NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression
- PMGC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- PMGC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- PMGC Holdings Inc. Announces Merger of AGA Precision Systems into A&B Aerospace
- Wall Street is Watching These Biotechs
- PMGC Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences
- NorthStrive Biosciences Files Two New U.S. Patent Applications Targeting Muscle Preservation in GLP-1 and Next-Generation Obesity Treatment Markets
- PMGC Holdings Highlights Advanced Precision Manufacturing Capabilities Supporting Space Exploration Supply Chains
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S